Comment on 'Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism': Author's response

摘要

I would like to thank Drs Terplan and Zuckerman for their comments1 on the recently published position statement,2 which myself and the other cosignatory authors take very seriously.If I may summarise Drs Terplan and Zuckerman's argument. It starts with the assumption that there is now clear evidence proving that levonorgestel (LNG)- and norethisterone acetate (NETA)-containing combined oral contraceptives (COCs) have half the risk of all other combined hormonal contraceptives (oral, transdermal, transvaginal) containing four 'newer' progestogens, namely desogestrel, gestodene, drospirenone and cyproterone acetate.